ACH-806 (GS9132) is primarily investigated for its antiviral properties, particularly in the treatment of hepatitis C virus (HCV) infections. It functions as an HCV NS4A antagonist, targeting the viral replication process by inhibiting the formation of the HCV replication complex. This mechanism makes it a potential candidate for combination therapies aimed at enhancing antiviral efficacy and reducing resistance development. Research has shown its ability to suppress HCV RNA levels in clinical studies, suggesting its utility in improving treatment outcomes for patients with chronic hepatitis C. Its development underscores the ongoing efforts to identify novel therapeutic agents for managing viral infections.